$4.48
0.85%
Downside
Day's Volatility :6.48%
Upside
5.68%
88.51%
Downside
52 Weeks Volatility :97.32%
Upside
76.67%
Period | Canopy Growth Corporation | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -36.27% | 5.1% | 0.0% |
6 Months | 50.84% | 4.9% | 0.0% |
1 Year | -41.05% | 16.6% | 0.0% |
3 Years | -97.34% | 13.2% | -22.3% |
Market Capitalization | 527.8M |
Book Value | $6.58 |
Earnings Per Share (EPS) | -5.84 |
Wall Street Target Price | 4.28 |
Profit Margin | -259.94% |
Operating Margin TTM | -32.19% |
Return On Assets TTM | -3.83% |
Return On Equity TTM | -87.26% |
Revenue TTM | 287.1M |
Revenue Per Share TTM | 3.55 |
Quarterly Revenue Growth YOY | -13.200000000000001% |
Gross Profit TTM | -81.9M |
EBITDA | -59.4M |
Diluted Eps TTM | -5.84 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -4.21 |
EPS Estimate Next Year | -0.94 |
EPS Estimate Current Quarter | -0.34 |
EPS Estimate Next Quarter | -0.3 |
What analysts predicted
Downside of 4.46%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 169.5M | ↑ 190.37% |
Net Income | -501.7M | ↑ 1137.84% |
Net Profit Margin | -296.06% | ↓ 226.61% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 286.5M | ↑ 76.18% |
Net Income | -996.8M | ↑ 107.05% |
Net Profit Margin | -347.93% | ↓ 51.87% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 434.8M | ↑ 37.08% |
Net Income | -1.3B | ↑ 20.42% |
Net Profit Margin | -305.65% | ↑ 42.28% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 411.2M | ↓ 4.82% |
Net Income | -253.3M | ↓ 80.82% |
Net Profit Margin | -61.59% | ↑ 244.06% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 294.3M | ↓ 22.57% |
Net Income | -2.4B | ↑ 932.67% |
Net Profit Margin | -821.42% | ↓ 759.83% |
FY24 | Y/Y Change | |
---|---|---|
Revenue | 219.5M | ↓ 26.25% |
Net Income | -485.5M | ↓ 80.14% |
Net Profit Margin | -221.19% | ↑ 600.23% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 63.9M | ↓ 13.51% |
Net Income | -473.0M | ↑ 142.8% |
Net Profit Margin | -739.83% | ↓ 476.3% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 81.8M | ↑ 24.21% |
Net Income | -28.7M | ↓ 94.11% |
Net Profit Margin | -35.06% | ↑ 704.77% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 60.6M | ↓ 24.51% |
Net Income | -228.8M | ↑ 713.24% |
Net Profit Margin | -377.72% | ↓ 342.66% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 58.5M | ↓ 4.35% |
Net Income | -161.6M | ↓ 30.07% |
Net Profit Margin | -276.16% | ↑ 101.56% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 39.7M | ↓ 31.56% |
Net Income | -50.3M | ↓ 68.56% |
Net Profit Margin | -126.86% | ↑ 149.3% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 35.3M | ↓ 9.96% |
Net Income | -67.8M | ↑ 36.29% |
Net Profit Margin | -192.02% | ↓ 65.16% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 6.5B | ↑ 507.72% |
Total Liabilities | 1.1B | ↑ 669.9% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 4.9B | ↓ 21.46% |
Total Liabilities | 1.2B | ↑ 12.72% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 5.4B | ↓ 0.5% |
Total Liabilities | 2.5B | ↑ 90.59% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 4.4B | ↓ 17.71% |
Total Liabilities | 1.6B | ↓ 38.01% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 1.8B | ↓ 56.56% |
Total Liabilities | 1.2B | ↓ 15.39% |
FY24 | Y/Y Change | |
---|---|---|
Total Assets | 960.5M | ↓ 46.69% |
Total Liabilities | 590.8M | ↓ 52.37% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.8B | ↓ 19.24% |
Total Liabilities | 1.2B | ↑ 6.24% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.6B | ↓ 10.19% |
Total Liabilities | 1.0B | ↓ 20.01% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.2B | ↓ 23.84% |
Total Liabilities | 678.2M | ↓ 31.59% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.0B | ↓ 18.49% |
Total Liabilities | 607.6M | ↓ 11.28% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 709.0M | ↓ 29.41% |
Total Liabilities | 436.1M | ↓ 27.56% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 685.9M | ↓ 2.09% |
Total Liabilities | 401.7M | ↓ 6.77% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -389.7M | ↑ 538.62% |
Investing Cash Flow | -2.4B | ↑ 1343.75% |
Financing Cash Flow | 4.4B | ↑ 1010.05% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -555.1M | ↑ 48.44% |
Investing Cash Flow | -249.8M | ↓ 89.23% |
Financing Cash Flow | -41.1M | ↓ 100.98% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -370.4M | ↓ 39.72% |
Investing Cash Flow | -703.1M | ↑ 154.31% |
Financing Cash Flow | 1.0B | ↓ 2312.64% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -431.3M | ↑ 17.19% |
Investing Cash Flow | 182.4M | ↓ 126.11% |
Financing Cash Flow | -36.0M | ↓ 103.6% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -102.1M | ↓ 2.89% |
Investing Cash Flow | 104.1M | ↑ 5.51% |
Financing Cash Flow | 92.2M | ↓ 194.55% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -111.9M | ↑ 6.39% |
Investing Cash Flow | 107.3M | ↑ 0.0% |
Financing Cash Flow | -100.2M | ↓ 205.45% |
Sell
Neutral
Buy
Canopy Growth Corporation is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Canopy Growth Corporation | -29.89% | 50.84% | -41.05% | -97.34% | -98.35% |
![]() Neurocrine Biosciences Inc. | -16.62% | -11.2% | 10.78% | 28.21% | 20.17% |
![]() Haleon Plc Spon Ads | 7.49% | 20.82% | 28.48% | 39.41% | 39.41% |
![]() Zoetis Inc. | 2.41% | 4.25% | 0.77% | -8.94% | 49.4% |
![]() Viatris Inc. | -0.79% | -8.6% | 12.7% | -23.12% | -31.03% |
![]() Catalent, Inc. | 0.82% | 6.48% | 22.57% | -57.47% | 16.16% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Canopy Growth Corporation | NA | NA | NA | -4.21 | -0.87 | -0.04 | NA | 6.58 |
![]() Neurocrine Biosciences Inc. | 36.53 | 36.53 | 0.27 | 4.57 | 0.16 | 0.12 | NA | 24.87 |
![]() Haleon Plc Spon Ads | 33.32 | 33.32 | 1.47 | 0.39 | 0.07 | 0.04 | 0.02 | 1.82 |
![]() Zoetis Inc. | 36.6 | 36.6 | 2.61 | 5.82 | 0.49 | 0.14 | 0.01 | 10.94 |
![]() Viatris Inc. | 224.4 | NA | 0.07 | 2.68 | -0.03 | 0.03 | 0.04 | 16.36 |
![]() Catalent, Inc. | 211.02 | NA | 2.87 | 0.2 | -0.25 | 0.0 | NA | 19.91 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Canopy Growth Corporation | Sell | $527.8M | -98.35% | NA | -259.94% |
![]() Neurocrine Biosciences Inc. | Buy | $12.2B | 20.17% | 36.53 | 16.0% |
![]() Haleon Plc Spon Ads | Buy | $47.1B | 39.41% | 33.32 | 9.66% |
![]() Zoetis Inc. | Buy | $85.7B | 49.4% | 36.6 | 26.29% |
![]() Viatris Inc. | Hold | $13.5B | -31.03% | 224.4 | -4.24% |
![]() Catalent, Inc. | Hold | $10.9B | 16.16% | 211.02 | -23.81% |
Insights on Canopy Growth Corporation
Revenue is down for the last 5 quarters, 108.72M → 48.38M (in $), with an average decrease of 17.6% per quarter
Netprofit is down for the last 2 quarters, -68.16M → -92.89M (in $), with an average decrease of 36.3% per quarter
In the last 1 year, Haleon Plc Spon Ads has given 28.5% return, outperforming this stock by 69.6%
Tidal Investments LLC.
Morgan Stanley - Brokerage Accounts
Two Sigma Investments LLC
Bank of America Corp
Ameriprise Financial Inc
Two Sigma Advisers, LLC
canopy growth corporation is a world-leading diversified cannabis company. we operate a collection of diverse brands and curated strain variety, supported millions of square feet of indoor greenhouse production capacity, partnered with some of the leading names in the sector. here's to future growth.
Organization | Canopy Growth Corporation |
Employees | 1029 |
CEO | Mr. David Eric Klein |
Industry | Process Industries |
A Spac I Acquisition Corp
$4.48
-5.49%
Keyarch Acquisition Corp
$4.48
-5.49%
Connexa Sports Technologies Inc
$4.48
-5.49%
Us Value Etf
$4.48
-5.49%
First Wave Biopharma Inc
$4.48
-5.49%
Global X Msci Next Emerging
$4.48
-5.49%
Fat Projects Acquisition Corp
$4.48
-5.49%
Capital Link Global Fintech
$4.48
-5.49%
Applied Uv Inc
$4.48
-5.49%